BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32729678)

  • 1. Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction.
    Cui X; Thunström E; Dahlström U; Zhou J; Ge J; Fu M
    ESC Heart Fail; 2020 Oct; 7(5):2894-2903. PubMed ID: 32729678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction.
    Santas E; de la Espriella R; Palau P; Miñana G; Amiguet M; Sanchis J; Lupón J; Bayes-Genís A; Chorro FJ; Núñez Villota J
    ESC Heart Fail; 2020 Jun; 7(3):1007-1014. PubMed ID: 32212327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
    Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
    ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design.
    Savarese G; Settergren C; Schrage B; Thorvaldsen T; Löfman I; Sartipy U; Mellbin L; Meyers A; Farsani SF; Brueckmann M; Brodovicz KG; Vedin O; Asselbergs FW; Dahlström U; Cosentino F; Lund LH
    Int J Cardiol; 2020 Aug; 313():76-82. PubMed ID: 32360702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
    Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
    Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
    Stolfo D; Uijl A; Vedin O; Strömberg A; Faxén UL; Rosano GMC; Sinagra G; Dahlström U; Savarese G
    JACC Heart Fail; 2019 Jun; 7(6):505-515. PubMed ID: 31146874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
    Chen X; Savarese G; Dahlström U; Lund LH; Fu M
    Clin Res Cardiol; 2019 Dec; 108(12):1394-1405. PubMed ID: 30980205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 13. Causes and Temporal Patterns of 30-Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction.
    Goyal P; Loop M; Chen L; Brown TM; Durant RW; Safford MM; Levitan EB
    J Am Heart Assoc; 2018 Apr; 7(9):. PubMed ID: 29686028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction.
    Teng TK; Tay WT; Dahlstrom U; Benson L; Lam CSP; Lund LH
    Int J Cardiol; 2018 Mar; 254():203-209. PubMed ID: 29407092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current conditions and significance of outpatient cardiac rehabilitation and home nursing-care services in heart failure patients with mid-range or preserved ejection fraction: post-hoc analysis of the REAL-HF registry.
    Kitagawa T; Hidaka T; Watanabe N; Naka M; Yamaguchi M; Kanai K; Isobe M; Kihara Y; Nakano Y;
    Heart Vessels; 2022 May; 37(5):745-754. PubMed ID: 34731295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
    Heart; 2018 Mar; 104(6):525-532. PubMed ID: 28982721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.
    Savarese G; Jonsson Å; Hallberg AC; Dahlström U; Edner M; Lund LH
    Int J Cardiol; 2020 Jan; 298():59-65. PubMed ID: 31521440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.
    Lyu S; Yu L; Tan H; Liu S; Liu X; Guo X; Zhu J
    BMC Cardiovasc Disord; 2019 Sep; 19(1):209. PubMed ID: 31477021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.